Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The role of protein corona on nanodrugs for organ-targeting and its prospects of application
S Wang, J Zhang, H Zhou, YC Lu, X **, L Luo… - Journal of Controlled …, 2023 - Elsevier
Nowadays, nanodrugs become a hotspot in the high-end medical field. They have the ability
to deliver drugs to reach their destination more effectively due to their unique properties and …
to deliver drugs to reach their destination more effectively due to their unique properties and …
The journey of a drug-carrier in the body: an anatomo-physiological perspective
Recent advances in chemistry and material sciences have witnessed the emergence of an
increasing number of novel and complex nanosized carriers for the delivery of drugs and …
increasing number of novel and complex nanosized carriers for the delivery of drugs and …
Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development
JFP Berbée, MR Boon, PPSJ Khedoe, A Bartelt… - Nature …, 2015 - nature.com
Brown adipose tissue (BAT) combusts high amounts of fatty acids, thereby lowering plasma
triglyceride levels and reducing obesity. However, the precise role of BAT in plasma …
triglyceride levels and reducing obesity. However, the precise role of BAT in plasma …
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine
The application of nanotechnology to personalized medicine provides an unprecedented
opportunity to improve the treatment of many diseases. Nanomaterials offer several …
opportunity to improve the treatment of many diseases. Nanomaterials offer several …
Controlling the stealth effect of nanocarriers through understanding the protein corona
S Schöttler, K Landfester… - Angewandte Chemie …, 2016 - Wiley Online Library
The past decade has seen a significant increase in interest in the use of polymeric
nanocarriers in medical applications. In particular, when used as drug vectors in targeted …
nanocarriers in medical applications. In particular, when used as drug vectors in targeted …
Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit
Objective Butyrate exerts metabolic benefits in mice and humans, the underlying
mechanisms being still unclear. We aimed to investigate the effect of butyrate on appetite …
mechanisms being still unclear. We aimed to investigate the effect of butyrate on appetite …
Injectable lipid emulsions—advancements, opportunities and challenges
K Hippalgaonkar, S Majumdar, V Kansara - Aaps Pharmscitech, 2010 - Springer
Injectable lipid emulsions, for decades, have been clinically used as an energy source for
hospitalized patients by providing essential fatty acids and vitamins. Recent interest in …
hospitalized patients by providing essential fatty acids and vitamins. Recent interest in …
Brown adipose tissue takes up plasma triglycerides mostly after lipolysis
PPSJ Khedoe, G Hoeke, S Kooijman, W Dijk… - Journal of lipid …, 2015 - jlr.org
Brown adipose tissue (BAT) produces heat by burning TGs that are stored within
intracellular lipid droplets and need to be replenished by the uptake of TG-derived FA from …
intracellular lipid droplets and need to be replenished by the uptake of TG-derived FA from …
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG …
ApoAV has been discovered recently as a novel modifier of triglyceride (TG) metabolism, but
the pathways involved are currently unknown. To gain insight into the function of apoAV …
the pathways involved are currently unknown. To gain insight into the function of apoAV …
Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis
Aims Fibroblast growth factor (FGF) 21, a key regulator of energy metabolism, is currently
evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis …
evaluated in humans for treatment of type 2 diabetes and non-alcoholic steatohepatitis …